icon
Getting Started
Health and Medicine
Pharmacy Times
2024-03-27

Navigating the Psychedelic Renaissance: Emerging Mental Health Therapies and the Pharmacist’s Role

Psychedelic medicines such as psilocybin, MDMA, ketamine, and LSD have been shown to have a significant impact on conditions such as major depressive disorder, generalized anxiety disorder, and post-traumatic stress disorder in clinical trials.

Related News

Live and Awake in LA

Having attended the surprisingly few SoCal events over the past few years, it was such a welcome pleasure to see familiar faces coming together in LA for 3 days of meaningful conversations centered around healing, community, access, learning, and networking at Psychedelic Awakening 2025 hosted by Psychedelic Institute of Los Angeles.

Read More icon
Most Of Mental Health Professionals Want Psychedelic Theraphy

A survey reveals that the majority of mental health professionals are open to psychedelic therapy, if legalized and properly regulated.

Read More icon
Can magic mushrooms mend the mind? Researchers map psilocybin’s mysterious brain effects – but key questions remain

Researchers found that psilocybin disrupts normal brain communication, increasing connectivity between different brain networks. These changes might explain psilocybin’s therapeutic effects, but questions remain about its true impact and how it influences feelings and behavior.

Read More icon
New Research Power Ups Psilocybin’s Potential as an Antidepressant

A team of researchers sought to determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs.

Read More icon
Why Indigenous “Spirit medicine‚” principles must be a priority in psychedelic research

Yuria Celidwen, a UC Berkeley Othering and Belonging Institute senior fellow, sheds light on how Western institutions can ethically approach the use of psychedelics.

Read More icon